Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 297-303

  Lindhagen, Elin ^a   Rickardson, Linda ^a   Elliott, Gary ^b   Leoni, Lorenzo ^b   Nygren, Peter ^a   Larsson, Rolf ^a   Åleskog, Anna ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b CEPHALON INC   (United States)

Author keywords

Anticancer drug; Etodolac; Indole pyran; SDX 101; SDX 308; SDX 309

Indexed keywords

ETODOLAC; PYRAN DERIVATIVE; SDX 101; SDX 308; SDX 309; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ETODOLAC; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS;

EID: 34250653640     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9049-4     Document Type: Article

References (15)

1. Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190:445-450
2. Patel MI, Subbaramaiah K, Du B et al (2005s) Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11:1999-2007
3. Johnson AJ, Smith LL, Zhu J et al (2005) A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 105:2504-2509
4. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080
5. Nardella FA, LeFevre JA (2002) Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Blood 99:2625-2626
6. Adachi S, Leoni LM, Carson DA, Nakahata T (2004) Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol 111:107-123
7. Lindhagen E, Nissle S, Leoni L et al (2006) R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 show potentiating cytotoxicity with standard cytotoxic agents in primary patient chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol (in press)
8. Lu D, Zhao Y, Tawatao R et al (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101:3118-3123
9. Bendall H, Bailey B, Reifert J et al (2004) SDX-101, a novel chemotherapeutic agent in clinical development, inhibits beta-catenin. Proceedings of the AACR 45
10. Kolluri SK, Corr M, James SY et al (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 102:2525-2530
11. Fridborg H, Jonsson E, Nygren P, Larsson R (1999) Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 35:424-432
12. Larsson R, Kristensen J, Sandberg C, Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50:177-185
13. Csoka K, Larsson R, Tholander B et al (1994) Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54:163-170
14. Dhar S, Nygren P, Csoka K et al (1996) Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 74:888-896
15. Yasui H, Hideshima T, Hamasaki M et al (2005) SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106:706-712